NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. (NAMS) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $0.50 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.3% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Holding B.V. is a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases. NewAmsterdam Pharma Holding B.V., formerly known as Frazier Lifesciences Acquisition Corporation, is based in MENLO PARK, Calif.
Sector
Healthcare
Industry
Drug Manufacturers/Other